MacroGenics, Servier Form Antibody Pact | Chemical & Engineering News
Volume 90 Issue 40 | p. 27 | Concentrates
Issue Date: October 1, 2012

MacroGenics, Servier Form Antibody Pact

Department: Business
Keywords: antibody, research and development, R&D

MacroGenics, a U.S.-based antibody therapeutics developer, and Servier, a French pharmaceutical company, have entered an agreement to develop and commercialize therapies aimed at three undisclosed tumor targets. They will use MacroGenics’ dual-affinity retargeting (DART) antibody platform. DART proteins can be used to redirect the body’s cell-destroying immune effector cells against tumors. MacroGenics will receive a $20 million up-front payment and retain full development and commercialization rights to the three preclinical DART programs in North America and Asia.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment